Phantom limb pain affects 64% of amputees but has no consensus treatment

Phantom limb pain -- the perception of pain in a limb that no longer exists -- affects approximately 64% of amputees, with some studies reporting lifetime prevalence as high as 87%. Despite this staggering prevalence, there is no standardized treatment protocol. A 2021 expert Delphi study could only reach consensus on seven treatments (mirror therapy, graded motor imagery, CBT, VR training, sensory discrimination, amitriptyline, and functional prosthesis use), and the evidence base for each remains weak. Clinicians resort to polypragmatic drug cocktails -- gabapentin, opioids, antidepressants -- prescribed through trial and error. This matters because phantom pain is not a minor annoyance: it causes chronic suffering, sleep disruption, and disability that compounds the already devastating impact of limb loss. The problem persists because the underlying neuroscience is poorly understood -- phantom pain involves maladaptive cortical reorganization that current imaging and treatment tools cannot precisely target. Funding for pain research is fragmented, and amputees are a small enough population that pharmaceutical companies have little incentive to run large-scale trials.